Condensed Financial Information of Parent Company - Schedule of Parent-only Statement of Cash Flows (Details) - USD ($)		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Changes in assets and liabilities:
Net cash provided by operating activities		$ 183,892,000	$ 138,292,000	$ 146,780,000
Cash flows from investing activities
Distribution from subsidiary		0	0	0
Net cash used in investing activities		(70,347,000)	(55,766,000)	(210,498,000)
Cash flows from financing activities
Repurchases of Class A common stock	[1]	(158,845,000)	(103,974,000)	(101,721,000)
Proceeds from exercise of stock options		19,046,000	5,941,000	9,159,000
Employee taxes paid related to net share settlement of equity awards		(29,784,000)	(65,481,000)	(20,635,000)
Proceeds from employee stock purchase plan		1,766,000	1,390,000	0
Net cash used in financing activities		(337,495,000)	(167,395,000)	(120,226,000)
Net change in cash and cash equivalents		(223,950,000)	(84,869,000)	(183,944,000)
Cash
Beginning of period		672,296,000	757,165,000	941,109,000
End of period		448,346,000	672,296,000	757,165,000
GoodRx Holdings, Inc
Cash flows from operating activities
Net income (loss)		16,390,000	(8,868,000)	(32,828,000)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Equity in (earnings) loss of subsidiary		(16,390,000)	8,868,000	32,828,000
Changes in assets and liabilities:
Other assets		164,000	(164,000)	80,000
Other current liabilities		(1,000)	1,000	0
Net cash provided by operating activities		163,000	(163,000)	80,000
Cash flows from investing activities
Distribution from subsidiary		167,679,000	162,287,000	113,117,000
Net cash used in investing activities		167,679,000	162,287,000	113,117,000
Cash flows from financing activities
Repurchases of Class A common stock		(158,845,000)	(103,974,000)	(101,721,000)
Proceeds from exercise of stock options		19,046,000	5,941,000	9,159,000
Employee taxes paid related to net share settlement of equity awards		(29,784,000)	(65,481,000)	(20,635,000)
Proceeds from employee stock purchase plan		1,766,000	1,390,000	0
Net cash used in financing activities		(167,817,000)	(162,124,000)	(113,197,000)
Net change in cash and cash equivalents		25,000	0	0
Cash
Beginning of period		5,000	5,000	5,000
End of period		$ 30,000	$ 5,000	$ 5,000

[1] Repurchases of Class A common stock for the year ended December 31, 2024 and 2023 include 20.9 million and 12.0 million shares repurchased from related parties (after giving effect to the automatic conversion of Class B common stock to Class A common stock upon such repurchase) for an aggregate consideration of $151.4 million, and $65.9 million, respectively. See "Note 14. Stockholders' Equity" for additional information.